UBS Upgrades InterMune (ITMN) to Neutral
More News related to ITMN
- Morning Movers 11/17: ZOOM, SMTL, AGO, ABCW, XJT Higher; INOC, QUIK, PSUN, ERI, FTK, TBUS Lower
- InterMune (ITMN) Modifies On-Going Phase 2b Study of ITMN-191
- InterMune Announces Modification to On-Going Phase 2b Study of ITMN-191 in Patients with Chronic HCV Infection
- InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
- InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
More News related to Upgrades
- Quest Capital (QCC) Pays $10M Toward Retiring Series A Preferred Shares
- IsoRay (ISR) Signs Distribution Agreement with Oncura for OncoSeed
- Simcere Pharma (SCR) Rabies Vaccine to be Investigated by China's SFDA
- Zhongpin (HOGS) Receives $3.1M From Chinese Gov't for Plant Improvement
- Goodrich Petrol (GDP) Announces Capital Budget for FY10; Updates on Haynesville and Cotton Valley Taylor Activities
UBS upgrades InterMune (Nasdaq: ITMN) from Sell to Neutral. Price target $13.
InterMune, Inc. (InterMune) is a biotech company focused on developing and commercializing therapies in pulmonology and hepatology.
To see more analyst ratings on ITMN Click Here.
Related Categories
UpgradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
